Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/61718
Type
ArticleCopyright
Restricted access
Collections
Metadata
Show full item record24
CITATIONS
24
Total citations
22
Recent citations
3.77
Field Citation Ratio
0.89
Relative Citation Ratio
SYNTHESIS OF EUDRAGIT® L100-COATED CHITOSAN-BASED NANOPARTICLES FOR ORAL ENOXAPARIN DELIVERY
Chitosan
Drug delivery system
Eudragit® L100
Low-molecular weight heparin
Polymer nanoparticles
Author
Affilliation
Federal University of Pernambuco. Quality Control Core of Medicines and Correlates. Recife, PE, Brazil.
Oswaldo Cruz Foundation. Aggeu Magalhães Institute. Department of Immunology. Recife, PE, Brazil.
Federal University of Delta of Parnaiba. Federal University of Delta of Parnaiba. Parnaiba, PI, Brazil.
Federal University of Pernambuco. Quality Control Core of Medicines and Correlates. Recife, PE, Brazil.
Oswaldo Cruz Foundation. Aggeu Magalhães Institute. Department of Immunology. Recife, PE, Brazil.
Federal University of Delta of Parnaiba. Federal University of Delta of Parnaiba. Parnaiba, PI, Brazil.
Federal University of Pernambuco. Quality Control Core of Medicines and Correlates. Recife, PE, Brazil.
Abstract
Enoxaparin is an effective biological molecule for prevention and treatment of coagulation disorders. However, it is poorly absorbed in the gastrointestinal tract. In this study, we developed an Eudragit® L100 coated chitosan core shell nanoparticles for enoxaparin oral delivery (Eud/CS/Enox NPs) through a completely eco-friendly method without employing any high-energy homogenizer technique and any organic solvents. Spherical nanocarriers were successfully prepared with particle size lower than 300 nm, polydispersity index about 0.12 and zeta potential higher than +25 mV, entrapment efficiency greater than 95% and the in vitro release behavior confirms the good colloidal stability and the successful Eudragit® L100 coating process demonstrated by negligible cumulative enoxaparin release (<10%) when the particles are submitted to simulated gastric fluid conditions. Finally, we demonstrated that the core-shell structure of the particle influenced the drug release mechanism of the formulations, indicating the presence of the Eudragit® L100 on the surface of the particles. These results suggested that enteric-coating approach and drug delivery nanotechnology can be successfully explored as potential tools for oral delivery of enoxaparin.
Keywords
BiomacromoleculeChitosan
Drug delivery system
Eudragit® L100
Low-molecular weight heparin
Polymer nanoparticles
Share